Citi is out with its report today on Watson Pharmaceuticals WPI, reiterating Buy.
In a note to clients, Citi writes, "WPI expects to launch Nulecit (a generic of SNY's Ferrlecit for treating iron deficiency anemia in chronic dialysis patients) in a few weeks following GeneraMedix's ANDA approval. Our model assumes Nulecit contributes 2011 sales/EPS of $30M (recorded in branded segment)/$0.05. The approval supported our ‘11E/‘12E EPS OF $4.02(+17%)/$5.08 (+27%) vs. the Street's $4.12 (+20%)/$5.15 (+28%). We reiterate our Buy rating on WPI."
Citi maintains a $67 PT on WPI.
Shares of WPI closed Thursday at $56.01.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: Analyst ColorPrice TargetAnalyst RatingsCitiHealth CarePharmaceuticalsWatson Pharmaceuticals
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in